Skip to content

Psilocybin

Psilocybin is a naturally occurring psychedelic compound found in certain mushrooms. It primarily acts on serotonin receptors in the brain, leading to altered perception and cognition. Psilocybin is being studied for its potential to enhance cognitive function and mental health, which can contribute to overall longevity and health optimization.

Intelligence Profile

Research Papers

Recent research on psilocybin, a psychedelic compound, has explored its therapeutic potential across various medical contexts.

  1. Psilocybin and Terminal Illness: A study published in Frontiers in Public Health examined a hybrid community therapy model for patients with terminal diagnoses. This approach combines traditional therapy with psilocybin to support mental health [PMID: 42548601].

  2. Cancer Treatment: A secondary analysis of a Phase II trial in the Journal of Pain and Symptom Management evaluated psilocybin's safety and efficacy during anticancer treatment. The study highlights its potential benefits in managing symptoms but specific sample sizes and outcomes are not detailed [PMID: 42546985].

  3. Fear of Cancer Recurrence: Published in Supportive Care in Cancer, this study focused on using psilocybin to mitigate fear in cancer survivors. It suggests promising applications, though the study's design specifics are not provided [PMID: 42541603].

  4. Anxiety and Depression in Metastatic Cancer: The Psychedelic Medicine journal reported on a Phase 1/2 study using group retreat formats for people with metastatic cancer. This format aims to address anxiety and depression through a rite of passage model [PMID: 42539893].

  5. Alcohol Use Disorder: Psilocybin-assisted therapy paired with a nature-themed intervention showed increased nature relatedness, potentially aiding recovery in alcohol use disorder, according to Psychedelic Medicine [PMID: 42539824].

  6. Treatment Resistant Depression: A completed Phase 2 clinical trial (NCT04739865) assessed psilocybin as an adjunctive therapy for treatment-resistant depression, indicating potential benefits.

  7. Persistent Effects: The trial NCT02971605 investigated the lasting effects of psilocybin, providing insight into its prolonged therapeutic impact.

Collectively, these studies and trials underscore psilocybin's potential across various therapeutic areas, particularly anxiety, depression, and substance use disorders. Further research is needed to establish consistent safety profiles and optimal treatment methodologies.

Disclaimer: This content is for informational purposes only and not a substitute for professional medical advice.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.